A multi-center, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and impact on health-related quality of life of levocetirizine 5 mg once daily given for 2 weeks in subjects 18 yr [year] of age and older with seasonal allergic rhinitis.

Trial Profile

A multi-center, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and impact on health-related quality of life of levocetirizine 5 mg once daily given for 2 weeks in subjects 18 yr [year] of age and older with seasonal allergic rhinitis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Levocetirizine (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 18 Nov 2009 Actual patient number changed from 567 to 580 as reported by ClinicalTrials.gov.
    • 25 Mar 2009 Actual patient number (567) added as reported by ClinicalTrials.gov.
    • 17 Jul 2008 Actual study completion date is now 1 Jul 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top